Investors and analysts have given it some thought and mostly think it's a sensible acquisition. Source: BioSpace

These stocks have been given a Strong Buy or Buy rating by 80% or more brokers. Source: BioSpace

Fresh off its $7B acquisition, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey. Source: BioSpace

This Latest move is a wide-ranging effort to boost competitiveness. Source: BioSpace

The 2016 U.S. presidential election was marked by aggressive and often shrill attacks on the biopharma industry over drug pricing. Source: BioSpace

After a two year absence, Aveo returned to the halls of the key event with a drug newly approved for use in Europe and possibly poised for approval in the…

Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly. Source: BioSpace

The company could be hoping the new hire will provide a consultative resource for all health-care regulatory issues. Source: BioSpace

With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference. Source: BioSpace

resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace